Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Jade Biosciences
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
May 26, 2026
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 29, 2026
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
April 29, 2026